Efficacy and safety study of herbal supplements (SR-L-01, SR-B-01 and SI-S-01) in the management of prediabetes and mild to moderate hyperlipidemia

Olive Lifesciences Pvt Ltd0 个研究点目标入组 40 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.As per ATP III guidelines: Baseline LDL ranging 160-189 mg/dL, TC >200 mg/dL and with no or one of the below risk factors
•Current cigarette smoking
•Family history of premature CHD (CHD in male first degree relative <55 years; CHD in female first degree relative <65 years)
•Hypertension (BP >=140/90 mmHg or on antihypertensive medication)
•Low HDL-C ( <40 mg/dL)
•Age (men >= 40 years; women >= 40 years)
•2.Impaired glucose tolerance (2-hour post 75 g OGTT glucose levels in the range of >=140 to <= 200 mg/dL)
•3.Impaired fasting sugar (FBS levels in the range of >= 100 to <=125 mg/dL)
•4.Being mentally competent and able to understand all study requirements and sign the informed consent form

•1.Patients with severe liver, renal, cardiac or brain diseases
•2.Pregnant or lactating women or women of childbearing potential whom are not practicing a reliable form of birth control (either with IUD or with stable usage of oral contraceptives)
•3.Unable to complete follow up
•4.Subjects on any medication that would affect evaluation like Statins
•5.Allergic to any medication
•6.With a history of alcohol and/or drug abuse

发起方

Olive Lifesciences Pvt Ltd